EXECUTIVE DECISION BRIEF

Turn weeks of technical review into a five-minute executive decision.

Executives don't need another investigation report. They need to understand what happened, why it matters, what decision was made, how defensible it is, and what requires action.

ComplianceWorxs converts complex compliance decisions into executive-ready briefings designed for senior leadership, regulators, investors, acquisition teams, legal counsel, and boards.

Generate Executive Decision Brief View Sample Executive Decision Brief →
EXECUTIVE DECISION BRIEF · CONFIDENTIAL
CAPA-2026-014 — Root Cause Closure
EXECUTIVE SUMMARY
A root-cause closure for a repeat deviation was authorized on partial evidence. The gap is defensible but narrow.
DECISION
Closed as operator error; no equipment requalification required.
RISK RATING
Defensible with Gaps
BUSINESS IMPACT
Release schedule unaffected; audit exposure if repeat event recurs before requalification.
RECOMMENDED ACTION
Schedule requalification within 30 days; document reasoning for the interim.
DECISION CONFIDENCE
82%
WHO THIS IS FOR

Built for the room where the decision gets made.

Six audiences. Six reasons the same underlying decision needs to be understood in five minutes, not fifty pages.

FDA Investigator
Needs the authorization logic in the room, not a walkthrough of the full file.
CEO
Needs to know the business exposure of a technical decision without reading the technical decision.
Board of Directors
Needs enough to ask the right question, not enough to re-litigate the science.
Private Equity
Needs to price the risk a quality decision carries into a deal, fast.
Acquisition Due Diligence
Needs a defensible summary of every material decision before close, not raw records.
Legal Counsel
Needs the decision framed the way it will be tested — before it's tested.
HOW IT WORKS

Three inputs. One document you can hand across a table.

01
Describe the decision
What was decided, on what evidence, and what's at stake if it's wrong.
02
Choose your audience
The same decision reads differently to a board than to an investigator. The brief adjusts.
03
Receive a tailored executive briefing
Summary, risk, impact, recommendation, and the questions leadership will ask — in one document.
BUILD THE BRIEF
SAMPLE OUTPUT — THIS IS WHAT YOU GET

This isn't another report. It's the document you hand your CEO.

Executive Decision Brief
Prepared for: VP Quality
Jul 07, 2026
EXECUTIVE SUMMARY
Lot 24P3487 was released without additional testing based on a borderline dissolution result. The decision is defensible but the residual exposure is not yet documented.
DECISION
Released to distribution without additional testing.
BUSINESS RISK
Moderate. Recall exposure is low; documentation exposure is not.
OPERATIONAL IMPACT
None to distribution schedule. One open action for QA to close within 15 days.
INSPECTION EXPOSURE
An investigator would ask why alternatives to release were not pursued. That answer exists but is not yet written down.
RECOMMENDATION
Approve as authorized; close the documentation gap before the next PAI window.
QUESTIONS LEADERSHIP WILL ASK
Who else reviewed this call, and would they make it again with the same evidence?
CONFIDENCE
High
RISK RATING
Defensible with Gaps
WHY EXECUTIVES USE IT

Clarity before consequence.

—
Explains complex investigations in minutes
—
Removes unnecessary technical detail
—
Highlights business exposure
—
Creates a common understanding before decisions are made
WHEN IT GETS USED

The moments where a five-minute document matters most.

FDA Inspection
Warning Letter
Board Meeting
Acquisition Due Diligence
Investor Review
Executive Escalation
Consent Decree
Major Deviation